Member Info for violindog

...and yet another subtle de-ramp by Crumbs

The slide presentation was very , very positive and really showed the potential of Scancell.

Vulps were openly critical of the "management" of Scancell and so too were LTHs...including myself.

The recent board appointments have certainly appeared to have transformed Scancell from a "" University spin off " into a forward looking " Clinical Pharmaceutical" company . It feels that we really are on the cusp of a major turnaround.

Botski - many thanks for the update .- amazing percentage !! I tried the link but couldnt get on .

WTP...your posts at 8:25 and 8:33 are spot on, the CPI majors will want to buy Scancell to extend patents.

Moonparty, Scancell may run a tight ship ..... but the other party may not !

Clearnerworld, thanks for all your excellent research. Your 11.11 post is indeed very interesting in relation to Texas Biomed beating the drum for Scancell, perhaps Covidity may indeed get some commercial result. I would like to think they had a word with the Senator about Covidity.....who knows.... but what a bonus if this happened !

C7, alot of what you say is correct. I guess the share registry of Scancell holds an awful lot of broken dreams as we stand at 10pence and not one pound . These broken dreams makes one angry ...both for yourself and other long term holders... and its human nature to lash out even at " virtual friends " especially when they start being negative after years of support. I have been guilty of this... for which I apologise. I'm still holding onto my dream . Its a shame, LTH have helped to build this company through all the capital raises only to give up now and hand over opportunity to new investors who will potentially gain from LTH efforts and years of support. I'm convinced all is not lost and all is still to play for.. and with the recent appointments - strengthening the board and the clinical focus on Scib and Moditope - we are not too far off reaching great potential. Whatever ones decision, I wish you all well... but I'm still keeping my dreams alive and will be reactive when you pi-- on Scancell and tell me its raining.

Reading the messages today and over the past few days ...Crumbs had turned into the very poster he used to criticise . His posts now contain a subtle ( or not so subtle) de-ramp of Scancell ...deliberately trying to weaken confidence ..but at the same time... spouts all is not lost to retain his "credibility" as a long term shareholder.

Good luck attempting to trade this as you turn from gamekeeper to poacher !!

WTP, excellent link re Trinity ..thanks. Did you notice in the report re Moditope the statement:

"One head & neck patient achieved a partial response and remains on study at week 37."

Interesting in relation to yesterday's events.

WTP, yes, head and neck that seeded lung cancer so not 100% convinced it's Moditope but as said earlier...this is the future of cancer treatment and the data is priceless.

Moditope or not...that article shows that the future of cancer treatment will be a mix of vaccines and CPI. Moditope will be commercial, I have no doubt, but it will be developed by a major having paid Scancell very well for the platform.

It's a competitive market and breakthroughs like Moditope won't be overlooked.

Crumbs....as someone who claims to hold Scancell shares ..you are certainly doing your best this evening to talk the company down. Strange indeed .

Burble makes an excellent point, one extra year of life, well lived, with reduced symptoms is a gift most terminal cancer patients would be desperate to grasp....and Crumbs says Moditope is not commercial !! The platform will need extra funding and development, we all know this including Scancell, Redmile / Vulps etc ..... but i am certain this trial will give enough data for Scancell to sell Moditope to the highest bidder. Crumbs ....it is commercial...even the data to date indicates this .

Good volume today being traded. Mostly all buys from this LSE site. So, hopefully the "Milan uptick" will soon be reflected in the sp.

Square, yes, some good volume and all look like buys...surprisingly we are marked down !

Come on guys ! ...when has Scancell ever promoted themselves.

The new Chairman has certainly had no evident affect on the share price .....and its too early to judge the new DB chap although initial SP market reaction was nil .

The only hope of shifting us back to recent heights is data ...data ... data ... so, as you guys say, roll on Milan and hopefully some deals an the back of it.

Always still hoping for an update on the Genmab deal or another deal announced / something from Moditope.

From the RNS info on the 10th of July...Scib/iScib is still years and years away from completion. We desperately need some large pharma to step in and take this off Scancell at a good price for us shareholders!

The alternative of no bid is a fundraising to see development through the next stages unless Moditope can flush something out.

"If positive, data generated by iSCIB1+ could lead to the initiation of a potential, rapid clinical development programme in H2 2024. An adapted registration trial could yield Phase 2 data within 2 years and would provide the Company with a pathway to a potential deal. The Phase 3 data could be complete within the following 3 years."

From the same rns ...Is Scancell still working on the mAbs or has this pipeline been mothballed to concentrate funds on scib / Moditope. I got this impression from the 10th July rns.

Looks to be all " in house" development but would obviously love them to be interested in anything Scancell has to offer....

"AbbVie has several new drugs in its portfolio with the potential to drive the top line and make up for lost Humira revenues. Newer products, Skyrizi and Rinvoq, are performing extremely well bolstered by approvals in new indications. "

Excellent summary Ruck !

...also to add ...potential further payment from Genmab may drop at any time .

One million dumped ?